Canaccord Genuity Cuts AngioDynamics Price Target

Medical device firm faces lower valuation amid market uncertainty

Apr. 9, 2026 at 7:56am

Got story updates? Submit your updates here. ›

A high-contrast black and white macro photograph of the complex internal components of a medical device, conveying the precision engineering and technical sophistication of AngioDynamics' product line.The inner workings of AngioDynamics' innovative medical devices reflect the technical expertise and engineering challenges facing the company as it navigates an uncertain market.Latham Today

Investment firm Canaccord Genuity Group has reduced its price target for AngioDynamics (NASDAQ:ANGO), a medical technology company that develops minimally invasive devices, from $18.00 to $16.00 per share. The analysts maintained a 'buy' rating on the stock, though several other research firms have issued more mixed or negative outlooks on the company's prospects.

Why it matters

AngioDynamics is a key player in the medical device industry, providing products focused on vascular access, peripheral vascular intervention, and interventional oncology. The company's stock performance and valuation are closely watched as indicators of broader trends in the sector, which has faced headwinds from the pandemic and economic uncertainty.

The details

In a research note, Canaccord Genuity analysts cited ongoing challenges facing AngioDynamics as the reason for the lower price target. Several other firms have also recently adjusted their ratings and forecasts for the company, with Weiss Ratings issuing a 'sell' recommendation, Zacks Research downgrading the stock to 'hold', and Wall Street Zen moving it from 'buy' to 'hold'. However, the overall analyst consensus remains a 'moderate buy' with an average target price of $18.67.

  • Canaccord Genuity released its updated research note on AngioDynamics on Monday, April 9, 2026.
  • AngioDynamics reported its latest quarterly earnings on Thursday, April 2, 2026.

The players

Canaccord Genuity Group

A global investment bank and financial services firm that provides research coverage on AngioDynamics.

AngioDynamics

A medical technology company headquartered in Latham, New York that develops minimally invasive medical devices focused on vascular access, peripheral vascular intervention, and interventional oncology.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching AngioDynamics' stock performance and any further updates from research analysts as the company navigates the current market environment.

The takeaway

The reduced price target from Canaccord Genuity reflects broader uncertainty facing the medical device industry, though AngioDynamics maintains a 'moderate buy' rating from analysts overall. The company's ability to weather economic headwinds and execute on its product pipeline will be key factors in determining its future valuation.